Immunotherapeutic potential of an N-formylated peptide of in experimental tuberculosis.

The current therapeutic regimens for tuberculosis (TB) are complex and involve the prolonged use of multiple antibiotics with diverse side effects that lead to therapeutic failure and bacterial resistance. The standard appliance of immunotherapy may aid as a powerful tool to combat the ensuing threat of TB. We have earlier reported the immunotherapeutic potential of N-formylated peptides of two secretory proteins of HRv. Here, we investigated the immunotherapeutic effect of an N-formylated peptide from in experimental TB. The N-terminally formylated listerial peptide with amino acid sequence 'f-MIGWII' was tested for its adjunctive therapeutic efficacy in combination with anti-tuberculosis drugs (ATDs) in the mouse model of TB. In addition, its potential to generate reactive oxygen species (ROS) in murine neutrophils was also evaluated The LemA peptide (f-MIGWII) induced a significant increase in the intracellular ROS levels of mouse neutrophils ( ≤ .05). The ATD treatment reduced the colony forming units (CFU) in lungs and spleen of infected mice by 2.39 and 1.67 log units, respectively ( < .001). Treatment of the infected mice with combination of ATDs and LemA peptide elicited higher therapeutic efficacy over ATDs alone. The histopathological changes in the lungs of infected mice also correlated well with the CFU data. Our results clearly indicate that LemA peptide conferred an additional therapeutic effect when given in combination with the ATDss ( < .01) and hence can be used as adjunct to the conventional chemotherapy against TB